8-K: BillionToOne Soars on Strong Q4, Raises 2026 Revenue Outlook

BillionToOne, Inc. reported robust fourth-quarter and full-year 2025 financial results, driven by significant revenue growth and improved profitability, leading to an upward revision of its 2026 revenue guidance.

Summary

• Total revenue for Q4 2025 increased by 113% to $96.1 million, compared to $45.1 million in Q4 2024.
• Full-year 2025 total revenue doubled to $305.1 million from $152.6 million in 2024.
• Gross profit margin improved significantly to 71% in Q4 2025 (from 57% in Q4 2024) and 68% for the full year 2025 (from 53% in 2024).
• The company achieved positive operating income of $10.3 million in Q4 2025 and $16.0 million for the full year 2025, a substantial turnaround from operating losses in 2024.
• Net income available to common shareholders was $4.4 million ($0.11 per diluted share) in Q4 2025 and $2.9 million ($0.14 per diluted share) for the full year 2025.
• BillionToOne raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, representing 41% to 46% growth over 2025.
• The company expects to achieve positive GAAP operating income for the full year 2026.
• Cash and cash equivalents stood at approximately $496.0 million as of December 31, 2025.
• New prenatal and oncology products were launched in Q1 2026, including expanded Red Blood Cell Fetal Antigen NIPT, Platelet Fetal Antigen NIPT, Northstar PGx, and Northstar Select CH.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, reflecting strong financial performance, significant operational improvements, and an optimistic outlook with raised guidance and new product launches, indicating robust growth momentum.

Positives

• Total revenue increased by 113% in Q4 2025 to $96.1 million and 100% for the full year 2025 to $305.1 million.
• Oncology clinical testing revenue grew over 8x (735%) in Q4 2025 to $9.1 million and 748% for the full year 2025 to $25.0 million.
• Gross profit margin significantly improved to 71% in Q4 2025 (up 14 percentage points) and 68% for the full year 2025 (up 15 percentage points).
• Achieved positive operating income of $10.3 million in Q4 2025 and $16.0 million for the full year 2025, a substantial improvement from losses in the prior year.
• Reported positive net income of $4.4 million in Q4 2025 and $2.9 million for the full year 2025.
• Raised full-year 2026 revenue guidance to $430 million to $445 million, indicating strong future growth expectations.
• Expects positive GAAP operating income for the full year 2026.
• Strong cash position with approximately $496.0 million in cash and cash equivalents as of December 31, 2025.
• Launched innovative new prenatal and oncology products in Q1 2026, expanding diagnostic capabilities.
• Net cash flow, excluding IPO proceeds, was positive at $8.8 million in Q4 2025 and $12.5 million for the full year 2025.
• Overall Average Selling Price (ASP) increased by 47% in Q4 2025 and 35% for the full year 2025.

Negatives

• Total operating expenses increased by 56% in Q4 2025 to $58.3 million and 50% for the full year 2025 to $192.4 million, outpacing revenue growth in percentage terms for Q4.
• Clinical Trial Support and Other Services revenue saw a slight decrease of 18% for the full year 2025 to $3.1 million.

Risks

• Actual outcomes and results could differ materially from forward-looking statements due to a number of factors, some beyond BillionToOne's control.
• Risks and uncertainties are discussed under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in the company's most recently filed quarterly report on Form 10-Q and the upcoming annual report on Form 10-K for the year ended December 31, 2025.
• The company disclaims any obligation to update forward-looking statements except as required by law.

Future Outlook

BillionToOne raised its full-year 2026 total revenue guidance to a range of $430 million to $445 million, representing 41% to 46% growth over 2025. The company also expects to achieve positive GAAP operating income for the full year 2026.

Management Comments

• "2025 demonstrated how the compounding power of a differentiated technology platform, category-defining products, and disciplined execution can produce an extraordinary outcome." Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne.
• "With new prenatal and oncology products already launched, expanding payer coverage, and a growing base of providers choosing our tests, we are executing to solve the hardest problems in healthcare and give patients the answers they need." Dr. Oguzhan Atay.
• "Entering 2026, we believe we are still in the earliest chapters of what is possible, and remain confident that our smNGS platform will continue to unlock diagnostic capabilities that transform patient lives one molecule at a time." Dr. Oguzhan Atay.

Industry Context

StockSavvy.ai notes that BillionToOne's strong performance and product launches in both prenatal and oncology diagnostics position it well within the rapidly expanding molecular diagnostics market. The introduction of specialized NIPT offerings for HDFN and FNAIT, alongside expanded oncology applications, demonstrates a strategic focus on niche, high-value segments, potentially differentiating it from broader diagnostic players by addressing critical unmet needs.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, improved profitability, raised revenue guidance, and new product launches, potentially leading to increased share value.
• Employees: Positive impact from the new Annual Incentive Plan, offering performance-based bonuses in cash or stock, enhancing motivation and retention.
• Customers (Healthcare Providers and Patients): Positive impact from the launch of new, specialized prenatal and oncology diagnostic tests, addressing critical health needs and expanding diagnostic capabilities.
• Creditors: Positive impact from improved financial health, positive operating income, and a strong cash position, indicating reduced credit risk.

Next Steps

• Host a conference call on March 4, 2026, at 1:30pm Pacific Time / 4:30pm Eastern Time to discuss financial results.
• File the full text of the BillionToOne Annual Incentive Plan as an exhibit to the company's Annual Report on Form 10-K for the year ended December 31, 2025.
• Continue expanding payer coverage and growing the base of providers choosing their tests.
• Further unlock diagnostic capabilities using the smNGS platform.

Key Dates

Recommendation

The company delivered exceptional Q4 and full-year 2025 results, demonstrating significant revenue growth, a remarkable turnaround to profitability, and substantial improvements in gross margins. The upward revision of 2026 revenue guidance and the expectation of positive GAAP operating income for the full year signal strong future momentum. The launch of innovative new products further strengthens its market position in high-growth diagnostic areas. These factors collectively present a compelling investment case for continued growth and value creation.

Keywords

Molecular diagnostics, Prenatal testing, Oncology testing, NIPT, smNGS platform, Financial results, Revenue guidance, Biotechnology, Healthcare diagnostics, Genetic testing